Clinical Efficacy Studies Chronic Glomerulonephritis Treatment Optimization Program

Objeetive:By treating chronic glomerulonephritis observed optimized solution in improving the clinical symptoms and the use of indicators, to further evaluate clinical medicine treatment of chronic glomerulonephritis Treatment optimization in the clinical efficacy and safety for the next a broader range of clinical use to provide evidence based medicine.Methods:Our hospital outpatient and inpatient clinical research since June20122013April40cases of chronic glomerulonephritis patients were treated with primary usefulness of randomized controlled using stratified random method of grouping blocks to the main center (Hospital) for the stratification factors, the qualified cases3:1into experimental and control groups to promote the observation that the test group of30patients in the control group of10patients. Both groups were given a regular basis, the treatment group was given Chinese dialectical treatment on this basis, and in accordance with the syndrome were divided into spleen Qi Deficiency, spleen and kidney yang deficiency of both gas, moisture, blood stasis, damp-heat. The control group received capsules Western Iosartan treatment. The treatment lasted six months,6months observed in patients with laboratory tests and clinical symptoms integration, which compare the clinical efficacy of the two groups of patients and level indicators.Results:The total clinical patients treated group was60.00%(18/30) was significantly higher in patients with30.00%(3/10), the difference through the X2test, its value is13.632, indicating that the difference was statistically significant (P<0.05) TCM Therapeutic; two groups of patients situation:clinical symptoms in patients with treatment group, the total efficiency of93.33%(28/30) was significantly higher in patients with30.00(3/10), the difference through X2test, its value is15.452, showed a statistically significant difference between the two groups (P<0.01); clinical laboratory indicators of major groups of patients:two groups of patients after treatment serum creatinine, blood urea nitrogen, Cys-C levels lower than before treatment, two the difference was statistically significant indicators of the level (P<0.05) in patients before and after treatment; creatinine treatment group and control group patients after treatment, blood urea nitrogen, Cys-C levels through the t test, two groups of patients after treatment the target level difference was not statistically significant (P>0.05); two adverse events comparison:the treatment group had delayed menstruation after taking a month and a half, not special treatment, after menstruation has returned to normal, patients with more than one patient no significant adverse events.Conelusion:TCM treatment efficacy in patients with chronic glomerulonephritis exact, can significantly improve the overall clinical symptoms of chronic nephritis patients, laboratory parameters to reduce proteinuria and improve renal function in patients taking the medicine during the toxic side effects, easy to make patients receiving long-term, worthy of clinical application.